A Step Forward for Long-Acting PCSK9 Inhibition DOI
Raúl D. Santos, Khurram Nasir, Michael D. Shapiro

et al.

Journal of the American College of Cardiology, Journal Year: 2024, Volume and Issue: 84(20), P. 2048 - 2050

Published: Oct. 9, 2024

Language: Английский

Angiopoietin-Like 3 Antibody Therapy in Patients With Suboptimally Controlled Hyperlipidemia DOI
Xiaojie Xie, Xiaoxia Shi,

Yuming Zhang

et al.

Journal of the American College of Cardiology, Journal Year: 2025, Volume and Issue: unknown

Published: March 1, 2025

Language: Английский

Citations

1
Antibodies to watch in 2025 DOI Creative Commons
Silvia Crescioli, Hélène Kaplon, Lin Wang

et al.

mAbs, Journal Year: 2024, Volume and Issue: 17(1)

Published: Dec. 22, 2024

The commercial development of antibody therapeutics is a global enterprise involving thousands biopharmaceutical firms and supporting service organizations. To date, their combined efforts have resulted in over 200 marketed pipeline nearly 1,400 investigational product candidates that are undergoing evaluation clinical studies as treatments for wide variety diseases. Here, we discuss key events occurred during 2024 forecast related to the late-stage may occur 2025. In particular, report on 21 granted first approval at least one country or region 2024, including bispecific antibodies tarlatamab (IMDELLTRA®), zanidatamab (Ziihera®), zenocutuzumab (BIZENGRI®), odronextamab (Ordspono®), ivonescimab (依達方®), antibody–drug conjugate (ADC) sacituzumab tirumotecan (佳泰萊®). We also 30 which marketing applications were review by regulatory agency, our last update December 9, ADCs datopotamab deruxtecan, telisotuzumab vedotin, patritumab trastuzumab botidotin, becotatug rezetecan. Of 178 include pipeline, summarize data 18 be submitted end 2025, such bi- multispecific denecimig, sonelokimab, erfonrilimab, anbenitamab. Key trends formats bispecifics ADCs, well clinical-phase transition success rates these formats, reported.

Language: Английский

Citations

4
Targeting PCSK9 beyond the liver: evidence from experimental and clinical studies DOI
Lorenzo Da Dalt, Andrea Baragetti, Giuseppe Danilo Norata

et al.

Expert Opinion on Therapeutic Targets, Journal Year: 2025, Volume and Issue: unknown

Published: March 20, 2025

PCSK9 has been widely studied as a target for lipid-lowering its inhibition increases LDL-R recycling on the surface of hepatocytes, which promotes catabolism LDL particles.PCSK9 can be synthesized in extra-hepatic tissues, including brain, pancreas, heart, and immune cells. This is interest to understand whether effects observed when genetically inhibited by naturally occurring mutations are also recapitulated pharmacology. Genetics studies reported an increased risk developing new-onset diabetes, ectopic adiposity reduced immune-inflammatory responses with deficiency. However, these aspects were not clinical trials data from real world medicine monoclonal antibodies (mAbs) gene silencing approaches targeting PCSK9. It possible that biological adaptations lifelong, case genetic studies, could explain discrepancy obtained testing pharmacological Also, mAbs have use 12 years, thus probably, this time window, reduction circulating up 80-90% does lead changes other than impressive LDL-C CVD events.

Language: Английский

Citations

0
A Phase I Study to Evaluate the Relative Bioavailability, Pharmacodynamics, and Safety of a Single Subcutaneous Injection of Recaticimab at Three Different Sites in Healthy Chinese Subjects DOI
Ying Wang, Yuanzhi Cheng, Yuhan Guo

et al.

European Journal of Drug Metabolism and Pharmacokinetics, Journal Year: 2025, Volume and Issue: unknown

Published: April 19, 2025

Language: Английский

Citations

0
Oral PCSK9 Inhibitors: Will They Work? DOI
Lâle Tokgözoğlu, Angela Pirillo, Alberico L. Catapano

et al.

Current Atherosclerosis Reports, Journal Year: 2025, Volume and Issue: 27(1)

Published: April 30, 2025

Language: Английский

Citations

0
A Step Forward for Long-Acting PCSK9 Inhibition DOI
Raúl D. Santos, Khurram Nasir, Michael D. Shapiro

et al.

Journal of the American College of Cardiology, Journal Year: 2024, Volume and Issue: 84(20), P. 2048 - 2050

Published: Oct. 9, 2024

Language: Английский

Citations

1